OncoDNA to attend the 36th European Congress of Pathology (ECP) in Florence

OncoDNA is taking part in the 36th European Congress of Pathology (ECP), to be held from 7 to 11 September 2024 in Florence, Italy. This event brings together pathology experts from across Europe to discuss the latest scientific advancements, emerging technologies, and cutting-edge clinical practices.

Discover the OncoDEEP® kit: the integrated solution for comprehensive genomic profiling (CGP)

  • At ECP, we will showcase the OncoDEEP® kit, our comprehensive genomic profiling (CGP) solution designed to transform laboratory workflows. The OncoDEEP® kit enables the analysis of hundreds of genes, including key cancer biomarkers for therapy decisions, all within a single assay. What sets this integrated solution apart is:
    Comprehensive genomic profiling: Use OncoDEEP® as a kit in your laboratory or through our centralized service.
  • Integrated pan-cancer solution: Detect NGS variants and complex biomarkers, including HRD, through a single CGP workflow, reducing the need for additional testing.
  • Efficient laboratory management: Lower costs by processing 3 times more samples per flow cell while meeting clinical turnaround targets.
  • Technology-neutral genomic profiling: Compatible with various wet lab automation and sequencing platforms.

From DNA to clinical reports: The OncoDEEP® kit includes reagents, integrated analysis, and clinically actionable reports generated by OncoKDM™.
Strategic oncology insight: Leverage local laboratory data with access to benchmarking tools.

Meet our experts at ECP
We invite you to visit us at booth #70 to discover how our solutions can optimize your laboratory’s workflow and deliver more precise, faster results to oncologists and their patients. Our team will be available to answer your questions, discuss your lab’s specific needs, and share case studies from satisfied customers across Europe and beyond.


Book your slot now to meet our experts at ECP: https://oncodna.com/ecp_september24/

For more details about the OncoDEEP® kit and how it can benefit your laboratory, visit our dedicated OncoDEEP kit page.


We look forward to seeing you in Florence to share our latest innovations in precision oncology and pathology!

 
 

You may also be interested in these resources

Scientific Application Note

Lung Cancer : Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis

Abstract Aim: To assess time-to-treatment failure (TTF) in US patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib–osimertinib treatment in the global, observational GioTag study.  Patients & methods: Patients had EGFR T790M mutation-positive disease after first-line afatinib and...

Scientific Application Note

HEPATOCELLULAR CANCER Combination PD-L1 and VEGFR inhibition (atezolizumab plus bevacizumab) delivered better overall and progression-free survival than standard of care sorafenib in a pivotal phase 3 study.

ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA Richard S. Finn et al N Engl J Med 2020; 382:1894-1905 BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b...

Share This